Jiwei Liu

8.6k total citations
65 papers, 1.4k citations indexed

About

Jiwei Liu is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jiwei Liu has authored 65 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 27 papers in Oncology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jiwei Liu's work include Lung Cancer Treatments and Mutations (10 papers), Ubiquitin and proteasome pathways (9 papers) and Lung Cancer Research Studies (8 papers). Jiwei Liu is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Ubiquitin and proteasome pathways (9 papers) and Lung Cancer Research Studies (8 papers). Jiwei Liu collaborates with scholars based in China, United States and Singapore. Jiwei Liu's co-authors include Qiu Yan, Aman Wang, Di Wang, Xiu Shan, Xiaoqi Wang, Zhen Ning, Xiaodong Li, Lili Tian, Qun Chen and Yi Zhao and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Journal of Hazardous Materials.

In The Last Decade

Jiwei Liu

58 papers receiving 1.4k citations

Peers

Jiwei Liu
Aya Naiki‐Ito Japan
Debra A. Tonetti United States
Uma Giri United States
Yuping Yin China
David P. Labbé Canada
Youquan Bu China
Wen Xia China
Min Zheng China
Meiying Zhang China
Aya Naiki‐Ito Japan
Jiwei Liu
Citations per year, relative to Jiwei Liu Jiwei Liu (= 1×) peers Aya Naiki‐Ito

Countries citing papers authored by Jiwei Liu

Since Specialization
Citations

This map shows the geographic impact of Jiwei Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiwei Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiwei Liu more than expected).

Fields of papers citing papers by Jiwei Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiwei Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiwei Liu. The network helps show where Jiwei Liu may publish in the future.

Co-authorship network of co-authors of Jiwei Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Jiwei Liu. A scholar is included among the top collaborators of Jiwei Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiwei Liu. Jiwei Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xia, Wei, Jiwei Liu, Ruo Chen, et al.. (2025). Molecular subtypes and prognostic signature rooted in disulfidptosis highlight tumor microenvironment in lung adenocarcinoma. Chinese Journal of Cancer Research. 37(5). 796–820.
2.
Jin, Chen, Xiang Ji, Yansong Liu, et al.. (2025). E3 ligase TRIM22 promotes melanoma proliferation by regulating cell cycle progression through K63-linked ubiquitination of p21. Scientific Reports. 15(1). 22311–22311.
3.
Ding, Haizhen, Jiwei Liu, Qin Liu, et al.. (2024). Risk assessment and source tracing of heavy metals in major rice-producing provinces of Yangtze River Basin. Journal of Hazardous Materials. 480. 136206–136206. 12 indexed citations
4.
Wei, Xiaoting, Zhengyun Zou, Weizhen Zhang, et al.. (2024). Overall survival and efficacy subgroup analysis of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.. Journal of Clinical Oncology. 42(16_suppl). 9545–9545. 3 indexed citations
5.
Cheng, Ying, James C. Yang, Isamu Okamoto, et al.. (2023). Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia. Immunotherapy. 15(13). 1029–1044. 3 indexed citations
6.
Si, Lu, Zhengyun Zou, Weizhen Zhang, et al.. (2023). Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.. Journal of Clinical Oncology. 41(16_suppl). 9510–9510. 5 indexed citations
7.
Cheng, Ying, Li Zhang, Jie Hu, et al.. (2021). Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407. JTO Clinical and Research Reports. 2(10). 100225–100225. 29 indexed citations
8.
Safi, Mohammed, Mahmoud Al‐Azab, Dario Trapani, et al.. (2021). Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI) Versus Non-ICI Era: A Population-Based Study. Frontiers in Immunology. 12. 609728–609728. 12 indexed citations
9.
Yang, Lu-Ping, Zixian Wang, Rui Zhang, et al.. (2021). Association between cigarette smoking and colorectal cancer sidedness: A multi-center big-data platform-based analysis. Journal of Translational Medicine. 19(1). 150–150. 14 indexed citations
10.
Shan, Xiu, Weijie Dong, Li Zhang, et al.. (2020). Role of fucosyltransferase IV in the migration and invasion of human melanoma cells. IUBMB Life. 72(5). 942–956. 8 indexed citations
11.
Zhang, Li, Xiu Shan, Qun Chen, et al.. (2019). Downregulation of HDAC3 by ginsenoside Rg3 inhibits epithelial–mesenchymal transition of cutaneous squamous cell carcinoma through c‐Jun acetylation. Journal of Cellular Physiology. 234(12). 22207–22219. 23 indexed citations
12.
Chen, Di, Zhen Ning, Huan Chen, et al.. (2019). An integrative pan-cancer analysis of biological and clinical impacts underlying ubiquitin-specific-processing proteases. Oncogene. 39(3). 587–602. 13 indexed citations
13.
Si, Lu, Xiaoshi Zhang, Yongqian Shu, et al.. (2019). A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). Translational Oncology. 12(6). 828–835. 99 indexed citations
14.
Wang, Di, et al.. (2018). Biosynthesis of selenium nanoparticles, characterization and X-ray induced radiotherapy for the treatment of lung cancer with interstitial lung disease. Journal of Photochemistry and Photobiology B Biology. 191. 123–127. 87 indexed citations
15.
Li, Zhen, Ke Jiang, Xiaofang Zhu, et al.. (2015). Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Letters. 370(2). 332–344. 86 indexed citations
16.
17.
Ning, Zhen, Aman Wang, Jinxiao Liang, et al.. (2014). USP22 promotes epithelial-mesenchymal transition via the FAK pathway in pancreatic cancer cells. Oncology Reports. 32(4). 1451–1458. 37 indexed citations
18.
Gao, Jingchun, Yi Zhao, Bing Wei, et al.. (2013). Mirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells. Cancer Cell International. 13(1). 2–2. 43 indexed citations
19.
Fang, Fengqi, et al.. (2012). Anti-cancer effects of 2-oxoquinoline derivatives on the HCT116 and LoVo human colon cancer cell lines. Molecular Medicine Reports. 12(6). 8062–8070. 7 indexed citations
20.
Chen, Junxia, et al.. (2005). Antitumor effects of human ribonuclease inhibitor gene transfected on B16 melanoma cells. The International Journal of Biochemistry & Cell Biology. 37(6). 1219–1231. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aya Naiki‐Ito Breakdown of academic impact, for papers by Debra A. Tonetti Breakdown of academic impact, for papers by Uma Giri Breakdown of academic impact, for papers by Yuping Yin Breakdown of academic impact, for papers by David P. Labbé Breakdown of academic impact, for papers by Youquan Bu Breakdown of academic impact, for papers by Wen Xia Breakdown of academic impact, for papers by Min Zheng Breakdown of academic impact, for papers by Meiying Zhang
Rankless by CCL
2026